Please login to the form below

Not currently logged in
Email:
Password:

SkyePharma soars as EC backs Flutiform approval

Prepares to launch asthma drug in EU after demanding regulatory process

UK drug delivery specialist SkyePharma and partner Mundipharma are celebrating after the European Commission approved their combination asthma drug Flutiform, setting up launches of the product across the EU in the second half of 2012.

The approval comes after a long regulatory route for Flutiform (fluticasone/formoterol) that saw the application referred to the European Medicines Agency (EMA) after EU member states were unable to agree on approval via the decentralised procedure.

The referral had prompted speculation that Flutiform's EU launches could be delayed by several months, but in fact the rapid review by the EMA means it has only been delayed by a few weeks.

Meanwhile, in 2010 the FDA rejected SkyePharma's application for Flutiform as a treatment for asthma, asking for additional clinical studies on dosing that have substantially delaying its approval in the US. That delay cost the UK firm a marketing alliance for the drug with Abbott Laboratories.

Now, with EU endorsement in place, Mundipharma plans to move ahead with launching the product "as soon as possible through its network of independent associated companies once national approvals are granted and reimbursement confirmed".

Shares in SkyePharma climbed more than a third as the news broke yesterday but fell back a little to close up 25 per cent higher at 98 pence.

"To get a product of this complexity through to approval has been an immense achievement by SkyePharma and our partner Mundipharma," said chief executive Peter Grant, who took over the helm of the company earlier this year upon the resignation of former CEO Axel Mueller.

Skyepharma stands to earn milestones of up to €15m in instalments as the product is launched in major European markets, as part of a €73m deal signed with Mundipharma, with another €40m available based on sales performance. The company has already received around €18m in upfront and development milestones.

Mundipharma has marketing rights to Flutiform in the EU, as well as most other territories outside Japan and the Americas.

4th July 2012

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Free White Paper: Customer Experience for Pharma
To learn why an effective customer experience strategy is vital for pharma, download our white paper “Customer experience for pharma” to learn more....
How ethical is your brand plan? Introducing the hEQ.
Assess your brand plan’s Healthcare Ethics Quotient and see how these questions can give your brand plan a new perspective and engage your internal teams and external customers....
solution_options.png
Why e-detailing must give options to healthcare professionals
We know, we know. You want to talk about your treatment right away, but this really is an essential step that will make your e-detailing even more credible....